

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

March 26, 2001

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS

Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that it has entered into a definitive agreement with
privately-held Path Lab Holdings, Inc. (Path Lab) to acquire
all of its outstanding stock. Path Lab, a leading regional
clinical laboratory established in 1971, is based in
Portsmouth, New Hampshire. Terms of the definitive
agreement were not disclosed. The transaction, which is
expected to be completed in approximately one month, is
subject to certain, normal closing conditions including
expiration of the waiting periods under the Hart Scott
Rodino Antitrust Improvements Act.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS

- (c) Exhibit
Press release of the Company dated March 26,
2001.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By: /s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer

Date: March 26, 2001

Laboratory Corporation of America-Registered Trademark-Holdings
358 South Main Street
Burlington, NC 27215
Telephone: 336-584-5171

FOR IMMEDIATE RELEASE

Contact: 336-436-4855
Pamela Sherry

Shareholder Direct: 800-LAB-0401
www.labcorp.com

LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK-
ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE PATH LAB IN NEW ENGLAND

Burlington, NC, March 26, 2001 - Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-) (NYSE: LH) today announced that it has entered into a definitive agreement with privately-held Path Lab Holdings, Inc. (Path Lab) to acquire all of its outstanding stock. Path Lab, a leading regional clinical laboratory established in 1971, is based in Portsmouth, New Hampshire. Terms of the definitive agreement were not disclosed. The transaction, which is expected to be completed in approximately one month, is subject to certain, normal closing conditions including expiration of the waiting periods under the Hart Scott Rodino Antitrust Improvements Act.

LabCorp plans to use Path Lab's facilities and seasoned management team to form the cornerstone of its expansion into New England. Maintaining one full-service and three limited-service laboratories, as well as 38 patient service centers in New Hampshire, Massachusetts, Rhode Island and Maine, Path Lab will significantly improve LabCorp's service in those markets. Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity. These hospitals utilize Path Lab's lab management and information technology support programs for advanced connectivity and billing solutions.

"LabCorp currently has a limited presence in New England, while Path Lab has significant business in the area," noted Thomas P. Mac Mahon, chairman and chief executive officer. "Path Lab fits well into our strategy to make selective acquisitions. In this instance, we are expanding into New England with a company that has proven management expertise, particularly in hospital lab outsourcing and management, and in serving the esoteric testing needs of hospitals. The combination of Path Lab's excellent management team and solid regional presence strengthens our ability to effectively service current customers and to attract new customers in that region."

The first clinical laboratory to fully embrace genomic testing, Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-) has been a pioneer in commercializing new diagnostic technologies. As a national laboratory with annual revenues of \$1.9 billion in 2000 and over 18,000 employees, the company offers more than 4,000 clinical tests ranging from simple blood analyses to sophisticated molecular diagnostics. Serving over 200,000 clients nationwide, LabCorp leverages its expertise in innovative clinical testing technology with its Centers of Excellence. The Center for Molecular Biology and Pathology, in Research Triangle Park (RTP), North Carolina, develops applications for polymerase chain reaction (PCR) technology. LabCorp's National Genetics Institute in Los Angeles is an industry leader in developing novel, highly sensitive PCR methods for testing hepatitis C and other infectious agents, and its Center for Esoteric Testing in Burlington, North Carolina, performs the largest volume of specialty testing in the network. LabCorp's clients include physicians, state and federal government, managed care organizations, hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other clinical laboratories.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2000 and subsequent SEC filings.